Editors' Introduction to the Special Issue
Nigel Paneth and Michael J. Joyner ration of genetic information into health care (Letai 2017) . If only health-care providers would use host genomic information to decide which drugs to give their patients-whether with curative or preventive intent, whether based on the drugs suitability for the disease or for the patient-the results, we are told, would be transformative. The building blocks for the widespread adoption of precision medicine are well known (Aronson and Rehm 2015) . First, whole genome sequencing is to be performed on the entire population. Next, this genomic data must be linked with the human disease characteristics that geneticists like to refer to as the phenotype, using the large-scale study design referred to as the gene-wide association study (GWAS). The potential of GWAS studies has been enlarged in recent years by another massive biomedical investment, the creation of the electronic medical record, which is viewed as a reliable source of information about the clinical states under investigation. For all this to help patients, however, health-care providers must be educated in the nuances of genomics so that they know how to use this information to make the decisions that are promised to dramatically alter the health of the patient. The extraordinary array of assumptions that lie behind this rosy scenario have rarely been subject to serious discussion, although some occasional suggestions about problems have been made (Joyner and Paneth 2015) .
In this issue of Perspectives in Biology and Medicine, a multidisciplinary group of scientists take on these assumptions and hold them up to scrutiny from a variety of perspectives. The disciplines of the 15 authors include anthropology, epidemiology, genetics, immunology, microbiology, law, medicine, physiology, pharmacology, and public health. Our nine physician-authors have training in anesthesiology, cardiology, gastroenterology, pediatrics, infectious diseases, internal medicine, and global health.
Precision medicine is built on the same foundational assumption used to justify the HGP: that there is a tight linkage between an individual's genotype and clinical disease (Collins 1999) . This assumption leads to the expectation that information about the genome can predict disease risk with precision. But fundamental scientific and philosophical questions need to be asked about genomic research itself, and about how that research intersects with the biological matrix from which human genomic information is extracted, not to mention the societal matrix in which all human biology is embedded.
Questions about the epistemology of hypothesis-free big data in genomic medicine and its limitations are raised by Sui Huang, while Ana M. Soto and Carlos Sonnenschein address the limitations of reductionist approaches applied to the study of complex biomedical phenomena. The latter two authors propose switching to an organicist perspective-a theory of organisms-which they see as sorely needed to provide an appropriate foundation for the understanding of biological organization, and the framing of observations and experiments. All three authors consider the broader problem of how we infer causality in com-plex systems, raising serious questions about the capacity of big data to accurately predict disease.
Kenneth M. Weiss considers the conceptual biases implicit in the genomic research agenda-indeed, in the entire body of genomic thought going back to Mendel. He suggests that physiological traits like disease may involve patterning processes similar to those long recognized and genetically well understood for physical patterning, and that these patterning processes could provide a much-needed integrative, rather than the current "pointillist" (enumerative), approach. Michael J. Joyner, Lazslo G. Boros, and Gregory Fink explicate the remarkable capacity of organisms to create redundancy of function, raising yet further questions about the predictive value of the genome by itself.
As genomics moves from in vitro studies of the interiors of cells to the in vivo world of free human beings living in the population, it encounters further difficulties in inference. These can only be addressed through careful study design. Sandro Galea and Salma M. Abdalla set out the ways in which the precision medicine agenda, as manifest in its major current study, "All of Us," is limited by a failure to consider how unmeasured confounding and lack of generalizability can affect findings of human studies.
Nigel Paneth and Sten H. Vermund ask how the genomic age, which began long before the HGP, has impacted the health of the public. They find little of value to report on, and note that over the same time period, far less-celebrated advances in other areas of science and human behavior have produced extraordinary advances in human health, advances marked by substantial increases in longevity and reductions in key mortality and morbidity measures. Richard S. Cooper amplifies this message with his in-depth discussion of the revolution in cardiovascular health. Cooper notes that although there has been an 80% reduction in cardiovascular death rates in the US since the discovery of the molecular structure of DNA, this reduction in mortality owes nothing at all to that discovery or to any of its scientific legacies.
In the final set of articles, Timothy Caulfield applies his expertise in how exaggeration and inflation have impacted the world of science to the precision medicine universe, finding that it is saturated with "genohype." Ayaz Hyder next summarizes the extraordinary spending on the human genome and precision medicine and assesses the cost-effectiveness of the entire enterprise. And in another form of summing up, Arturo Casadevall argues that the period in which the genomic agenda has been central coincides with a possible loss of innovation and development in the biomedical sciences, a loss that threatens to reduce our tools to fight such challenges to humanity as new epidemics, climate change, and the next war against disease.
This Special Issue is not intended to provide both sides of what some see as a contentious discussion. Rather, in a world in which thousands of papers are written, dozens of conferences held, new departments in universities are created, and entire journals (Personalized Medicine, the Journal of Precision Medicine) are devoted to explication of the greatness of the precision medicine agenda, we feel it necessary to offer some cautionary thoughts.
This effort began with an excited email from Nigel Paneth to Michael Joyner after he read the latter's 2015 op-ed in the New York Times, "Moonshot Medicine Will Let Us Down." While each of us had quietly watched with dismay the over-hyped world of genomic medicine making promises that we knew could not possibly be met, we had not fully realized until our communication that what was going on was disturbing to the substantially different perspectives of a physiologist and an epidemiologist. We quickly found out that a number of scientists shared our concerns, and beginning with a small meeting in Boston in February 2016 (attended by Casadevall, Fink, Huang, Joyner, Paneth, Sonnenschein, and Soto), we reached out to a steadily expanding group of fellow scientists from virtually every discipline in biomedicine, from sociology to biochemistry, with whom we have conducted an email seminar and discussion over the past two and a half years.
The work in this issue is the distillation of some of that conversation, but we would like to note that several of our participants were not in a position to author a manuscript in this issue. They are acknowledged here because their thoughts and suggestions are built into much of which we have here written.
We also know that many biomedical scientists from outside our group who have not contributed to this current publishing effort share our concerns but are reluctant to express their views when funding, promotion, laboratory space, and much else is rewarded by adherence to the dominant cultural theme in today's biomedicine. That theme is the reductionist, genome-centered approach to human biology that sustains the fragile basis of precision medicine.
We hope that our contribution will permit an open conversation about all forms of biomedical endeavor intended to improve human health, and a greater openness to the many forms of biomedical research that have been crowded out by what we see as a narrow-minded, misguided, and indeed obsessive focus on the human genome.
